News: Gilead Sciences Inc (GILD.O)

GILD.O on Nasdaq

112.00USD
31 Oct 2014
Price Change (% chg)

$-2.22 (-1.94%)
Prev Close
$114.22
Open
$115.90
Day's High
$116.83
Day's Low
$110.76
Volume
22,070,031
Avg. Vol
14,594,643
52-wk High
$116.83
52-wk Low
$63.50

Search Stocks
Select another date:

Wed, Oct 29 2014

BRIEF-Express Scripts says may change formulary in mid-2015 due to "unsustainable" cost of Gilead's Sovaldi

Oct 29 - Express Scripts Holding Co : * Says may change drug formulary in mid-2015 to favor expected new hepatitis c

Gilead third-quarter Sovaldi sales dip, but net profit triples

- Gilead Sciences Inc , maker of $84,000 hepatitis C drug Sovaldi, on Tuesday said third quarter net profit more than tripled and product sales doubled, despite a dip in Sovaldi sales as doctors and patients awaited a recently approved combination pill.

UPDATE 2-Gilead third-quarter Sovaldi sales dip, but net profit triples

Oct 28 - Gilead Sciences Inc, maker of $84,000 hepatitis C drug Sovaldi, on Tuesday said third quarter net profit more than tripled and product sales doubled, despite a dip in Sovaldi sales as doctors and patients awaited a recently approved combination pill.

Gilead third-quarter profit triples as sales more than double

Oct 28 - Gilead Sciences Inc, maker of $84,000 hepatitis C drug Sovaldi, on Tuesday said third quarter net profit more than tripled and product sales doubled, despite a dip in Sovaldi sales as doctors and patients awaited a recently approved combination pill.

U.S. FDA approves Gilead's $94,500 hepatitis C drug

- U.S. regulators on Friday approved a new hepatitis C pill from Gilead Sciences Inc, which said it will charge $94,500 for an improved 12-week course of treatment to rid patients of the liver-destroying viral infection.

UPDATE 2-U.S. FDA approves Gilead's $94,500 hepatitis C drug

(Adds pharmacy benefit manager comment, analyst comment, background)

U.S. FDA approves Gilead's all-oral hepatitis C drug

Oct 10 - U.S. regulators on Friday approved Gilead Sciences Inc's all-oral hepatitis C drug, clearing the way for the company to increase its revenue from sales of treatments for the liver-destroying viral infection.

France uses tax to put pressure on hepatitis C drug prices

PARIS - France will tax drugmakers whose costly hepatitis C drugs threaten to throw off course its healthcare budget, the government has said, heaping pressure on pharmaceutical companies like Gilead Sciences to cut their prices.

France uses tax to put pressure on hepatitis C drug prices

PARIS, Sept 30 - France will tax drugmakers whose costly hepatitis C drugs threaten to throw off course its healthcare budget, the government has said, heaping pressure on pharmaceutical companies like Gilead Sciences to cut their prices.

US STOCKS-Biotechs climb after two-day drop

NEW YORK, Sept 24 - Biotech stocks are moving higher on Wednesday, bouncing back from a two-day drop, helped by gains in Gilead Sciences after trial results for the company's HIV treatment.

Select another date:

Press Releases

Search Stocks